摘要
心房颤动是临床上最常见的心律失常之一,心房颤动的全球流行率和发生率在不断上升。卒中和全身性血栓栓塞是心房颤动患者临床上最重要的并发症。亚洲人口快速老龄化,心房颤动相关性卒中的致死致残率高。心房颤动患者适当的卒中预防在亚洲至关重要。目前亚洲人群与非亚洲人群抗凝治疗风险、获益及策略仍存在争议,现对这两类人群抗凝现状及抗凝策略进行综述。
Atrial fibrillation（AF）is one of the most common cardiac arrhythmias in clinical practice.The global prevalence and incidence of atrial fibrillation are rising.Stroke and systemic thromboembolism are the most important complications in patients with AF.Rapid population aging in Asia has led to a high mortality and disability in AF-related stroke.Therefore,appropriate stroke prevention in AF patients is crucial in Asia.However,the strategies of anticoagulation and the risks,benefits in Asian and non-Asian populations remain controversial.This article reviews the anticoagulation strategies in both populations.
作者
闫静静
秦明照
YAN Jingjing;QIN Mingzhao(Department of Geriatrics,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)
出处
《心血管病学进展》
CAS
2018年第6期884-888,共5页
Advances in Cardiovascular Diseases
基金
北京市保健科研课题(京15-8号)
北京市科学技术委员会首都临床特色应用研究专项资助课题(Z161100000116079)
关键词
心房颤动
亚洲人
非亚洲人
抗凝治疗
Atrial fibrillation
Asian
Non-Asian populations
Anticoagulation therapy
